• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

    3.955 +0.025 (+0.64%)
    Streaming Delayed Price Updated: 3:15 PM EDT, Jun 18, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Iovance Biotherapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    23 24 Next >
    News headline image
    IOVANCE BIOTHERAPEUTICS DEADLINE IS JULY 14, 2025 - Investors are Encouraged to Contact Kaplan Fox
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Lawsuit
    News headline image
    IOVANCE BIOTHERAPEUTICS DEADLINE IS JULY 14, 2025 - Investors are Encouraged to Contact Kaplan Fox
    Via TheNewswire.com
    Topics Lawsuit
    News headline image
    IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVA
    From Kahn Swick & Foti, LLC
    Via GlobeNewswire
    News headline image
    Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Compass Diversified, Digimarc, Elevance Health, and Iovance and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    The Journal of Clinical Oncology Publishes Five-year Analysis of Amtagvi® (lifileucel) in Patients with Advanced Melanoma
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Robbins LLP Reminds IOVA Stockholders That a Class Action Lawsuit was Filed Against Iovance Biotherapeutics, Inc. Alleging the Company Misled Investors Regarding its Business Prospects
    From Robbins LLP
    Via GlobeNewswire
    News headline image
    IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVA
    From SkyMedia, LLC
    Via GlobeNewswire
    News headline image
    IOVA Investors Have the Opportunity to Lead the Iovance Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVA
    From Kahn Swick & Foti, LLC
    Via GlobeNewswire
    News headline image
    Kaplan Fox Alerts Investors of Iovance Biotherapeutics, Inc. (IOVA) to the Lead Plaintiff Deadline on July 14, 2025
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Lawsuit
    News headline image
    Kaplan Fox Alerts Investors of Iovance Biotherapeutics, Inc. (IOVA) to the Lead Plaintiff Deadline on July 14, 2025
    Via TheNewswire.com
    Topics Lawsuit
    News headline image
    IOVA Investors Have the Opportunity to Lead the Iovance Biotherapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting
    From Iovance Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVA
    From SkyMedia, LLC
    Via GlobeNewswire
    News headline image
    IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    News headline image
    ROSEN, LEADING INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVA
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 ↗
    Via The Motley Fool
    Topics Economy Law Enforcement
    News headline image
    FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC Continues Lead Plaintiff Search for Iovance Biotherapeutics, Inc. (IOVA) Securities Fraud Class Action
    From Kahn Swick & Foti, LLC
    Via GlobeNewswire
    News headline image
    Down More Than 75% This Year, Should Investors Throw in the Towel on Iovance Biotherapeutics Stock? ↗
    Via The Motley Fool
    News headline image
    Deadline Approaching: Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
    From Law Offices of Howard G. Smith
    Via Business Wire
    News headline image
    IOVA BREAKING NEWS: Iovance Biotherapeutics, Inc. Stock Plummets 44% Triggering Shareholder Class Action – Contact BFA Law if You Lost Money (NASDAQ:IOVA)
    From Bleichmar Fonti & Auld LLP
    Via Business Wire
    News headline image
    Law Offices of Frank R. Cruz Encourages Iovance Biotherapeutics, Inc. (IOVA) Investors To Inquire About Securities Fraud Class Action
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    News headline image
    Deadline Alert: Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
    From Glancy Prongay & Murray LLP
    Via Business Wire
    News headline image
    Kaplan Fox Encourages Investors of Iovance Biotherapeuitcs, Inc. (IOVA) to Contact the Firm Before Lead Plaintiff Deadline on July 14, 2025
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Lawsuit
    News headline image
    Kaplan Fox Encourages Investors of Iovance Biotherapeuitcs, Inc. (IOVA) to Contact the Firm Before Lead Plaintiff Deadline on July 14, 2025
    Via TheNewswire.com
    Topics Lawsuit
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    IOVA Investors Have the Opportunity to Lead the Iovance Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    23 24 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.